Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation
Objective To estimate the cost-effectiveness of providingHaemophilus influenzaetype b (Hib) vaccine to children in Moscow in routine immunization services. Methods The incidence of Hib meningitis among children aged
Gespeichert in:
| Veröffentlicht in: | Vaccine 2006-03, Vol.24 (13), p.2367 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 13 |
| container_start_page | 2367 |
| container_title | Vaccine |
| container_volume | 24 |
| creator | Platonov, AE Griffiths, UK Voeykova, MV Platonova, OV Shakhanina, IL Chistyakova, GG Robertson, SE |
| description | Objective To estimate the cost-effectiveness of providingHaemophilus influenzaetype b (Hib) vaccine to children in Moscow in routine immunization services. Methods The incidence of Hib meningitis among children aged |
| doi_str_mv | 10.1016/j.vaccine.2005.11.054 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1547142787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3379200111</sourcerecordid><originalsourceid>FETCH-proquest_journals_15471427873</originalsourceid><addsrcrecordid>eNqNjsFqwkAURYdSwdT6CcJAt810Xpwkdl0ibroRF10IMh1fcEIyL81kLPXrDcYP6OouzoFzGVuAFCAhe6vEWRtjHYpEylQACJmqBxbBKl_GSQqrRxbJJFOxAvk1ZU_eV3IQl_AesX1hyFFjDcezroPuLTlO5UZjQ-3J1sFz68o6oLto7P9a5N98rI2qdfyTvKHfV74N3lvt-BqP2N3oM5uUuvY4v--MvayL3ccmbjv6Cej7Q0WhcwM6QKpyUEk-XP6fdQViXU0Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547142787</pqid></control><display><type>article</type><title>Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation</title><source>Elsevier ScienceDirect Journals</source><creator>Platonov, AE ; Griffiths, UK ; Voeykova, MV ; Platonova, OV ; Shakhanina, IL ; Chistyakova, GG ; Robertson, SE</creator><creatorcontrib>Platonov, AE ; Griffiths, UK ; Voeykova, MV ; Platonova, OV ; Shakhanina, IL ; Chistyakova, GG ; Robertson, SE</creatorcontrib><description>Objective To estimate the cost-effectiveness of providingHaemophilus influenzaetype b (Hib) vaccine to children in Moscow in routine immunization services. Methods The incidence of Hib meningitis among children aged <5 years in Moscow was obtained from a prospective surveillance study undertaken during October 1999-September 2001, with treatment cost data collected for all cases. Sequelae in surviving children were assessed in December 2002. The costs of Hib vaccination in Moscow were estimated assuming a vaccine price of US$5 per dose and the same four-dose schedule and 97% coverage as for diphtheria-tetanus-pertussis vaccine. The most uncertain variables were varied in a sensitivity analysis. Results The annual incidence of Hib meningitis was 5.7 per 100,000 children <5 years. The average treatment cost for an acute Hib meningitis case was US$1296. For a patient with sequelae, the average additional lifetime discounted treatment cost was US$15,820. The total annual cost of Hib vaccination of infants in Moscow was estimated as US$1.5 million per year. In the base case analysis, the cost-effectiveness ratios amount to US$77,503 per Hib meningitis case averted and US$10,842 per discounted disability adjusted life year averted. The break-even vaccine price, where the annual vaccination costs equal annual treatment costs averted, is only US$0.04 per dose in the base case scenario. If discounted indirect costs are included, the break-even vaccine price is US$0.5 per dose. Conclusion In Moscow, the incidence of Hib meningitis is low and the costs of hospitalization and subsequent medical treatment are relatively inexpensive. Given these factors, Hib vaccine at US$5 per dose would not be a cost-effective option in Moscow at the present time.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2005.11.054</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><subject>Epidemiology ; Fatalities ; Immunization ; Medical treatment ; Meningitis ; Sensitivity analysis ; Vaccines</subject><ispartof>Vaccine, 2006-03, Vol.24 (13), p.2367</ispartof><rights>Copyright Elsevier Limited Mar 20, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Platonov, AE</creatorcontrib><creatorcontrib>Griffiths, UK</creatorcontrib><creatorcontrib>Voeykova, MV</creatorcontrib><creatorcontrib>Platonova, OV</creatorcontrib><creatorcontrib>Shakhanina, IL</creatorcontrib><creatorcontrib>Chistyakova, GG</creatorcontrib><creatorcontrib>Robertson, SE</creatorcontrib><title>Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation</title><title>Vaccine</title><description>Objective To estimate the cost-effectiveness of providingHaemophilus influenzaetype b (Hib) vaccine to children in Moscow in routine immunization services. Methods The incidence of Hib meningitis among children aged <5 years in Moscow was obtained from a prospective surveillance study undertaken during October 1999-September 2001, with treatment cost data collected for all cases. Sequelae in surviving children were assessed in December 2002. The costs of Hib vaccination in Moscow were estimated assuming a vaccine price of US$5 per dose and the same four-dose schedule and 97% coverage as for diphtheria-tetanus-pertussis vaccine. The most uncertain variables were varied in a sensitivity analysis. Results The annual incidence of Hib meningitis was 5.7 per 100,000 children <5 years. The average treatment cost for an acute Hib meningitis case was US$1296. For a patient with sequelae, the average additional lifetime discounted treatment cost was US$15,820. The total annual cost of Hib vaccination of infants in Moscow was estimated as US$1.5 million per year. In the base case analysis, the cost-effectiveness ratios amount to US$77,503 per Hib meningitis case averted and US$10,842 per discounted disability adjusted life year averted. The break-even vaccine price, where the annual vaccination costs equal annual treatment costs averted, is only US$0.04 per dose in the base case scenario. If discounted indirect costs are included, the break-even vaccine price is US$0.5 per dose. Conclusion In Moscow, the incidence of Hib meningitis is low and the costs of hospitalization and subsequent medical treatment are relatively inexpensive. Given these factors, Hib vaccine at US$5 per dose would not be a cost-effective option in Moscow at the present time.</description><subject>Epidemiology</subject><subject>Fatalities</subject><subject>Immunization</subject><subject>Medical treatment</subject><subject>Meningitis</subject><subject>Sensitivity analysis</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjsFqwkAURYdSwdT6CcJAt810Xpwkdl0ibroRF10IMh1fcEIyL81kLPXrDcYP6OouzoFzGVuAFCAhe6vEWRtjHYpEylQACJmqBxbBKl_GSQqrRxbJJFOxAvk1ZU_eV3IQl_AesX1hyFFjDcezroPuLTlO5UZjQ-3J1sFz68o6oLto7P9a5N98rI2qdfyTvKHfV74N3lvt-BqP2N3oM5uUuvY4v--MvayL3ccmbjv6Cej7Q0WhcwM6QKpyUEk-XP6fdQViXU0Z</recordid><startdate>20060320</startdate><enddate>20060320</enddate><creator>Platonov, AE</creator><creator>Griffiths, UK</creator><creator>Voeykova, MV</creator><creator>Platonova, OV</creator><creator>Shakhanina, IL</creator><creator>Chistyakova, GG</creator><creator>Robertson, SE</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20060320</creationdate><title>Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation</title><author>Platonov, AE ; Griffiths, UK ; Voeykova, MV ; Platonova, OV ; Shakhanina, IL ; Chistyakova, GG ; Robertson, SE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_15471427873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Epidemiology</topic><topic>Fatalities</topic><topic>Immunization</topic><topic>Medical treatment</topic><topic>Meningitis</topic><topic>Sensitivity analysis</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Platonov, AE</creatorcontrib><creatorcontrib>Griffiths, UK</creatorcontrib><creatorcontrib>Voeykova, MV</creatorcontrib><creatorcontrib>Platonova, OV</creatorcontrib><creatorcontrib>Shakhanina, IL</creatorcontrib><creatorcontrib>Chistyakova, GG</creatorcontrib><creatorcontrib>Robertson, SE</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Platonov, AE</au><au>Griffiths, UK</au><au>Voeykova, MV</au><au>Platonova, OV</au><au>Shakhanina, IL</au><au>Chistyakova, GG</au><au>Robertson, SE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation</atitle><jtitle>Vaccine</jtitle><date>2006-03-20</date><risdate>2006</risdate><volume>24</volume><issue>13</issue><spage>2367</spage><pages>2367-</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Objective To estimate the cost-effectiveness of providingHaemophilus influenzaetype b (Hib) vaccine to children in Moscow in routine immunization services. Methods The incidence of Hib meningitis among children aged <5 years in Moscow was obtained from a prospective surveillance study undertaken during October 1999-September 2001, with treatment cost data collected for all cases. Sequelae in surviving children were assessed in December 2002. The costs of Hib vaccination in Moscow were estimated assuming a vaccine price of US$5 per dose and the same four-dose schedule and 97% coverage as for diphtheria-tetanus-pertussis vaccine. The most uncertain variables were varied in a sensitivity analysis. Results The annual incidence of Hib meningitis was 5.7 per 100,000 children <5 years. The average treatment cost for an acute Hib meningitis case was US$1296. For a patient with sequelae, the average additional lifetime discounted treatment cost was US$15,820. The total annual cost of Hib vaccination of infants in Moscow was estimated as US$1.5 million per year. In the base case analysis, the cost-effectiveness ratios amount to US$77,503 per Hib meningitis case averted and US$10,842 per discounted disability adjusted life year averted. The break-even vaccine price, where the annual vaccination costs equal annual treatment costs averted, is only US$0.04 per dose in the base case scenario. If discounted indirect costs are included, the break-even vaccine price is US$0.5 per dose. Conclusion In Moscow, the incidence of Hib meningitis is low and the costs of hospitalization and subsequent medical treatment are relatively inexpensive. Given these factors, Hib vaccine at US$5 per dose would not be a cost-effective option in Moscow at the present time.</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1016/j.vaccine.2005.11.054</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2006-03, Vol.24 (13), p.2367 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_journals_1547142787 |
| source | Elsevier ScienceDirect Journals |
| subjects | Epidemiology Fatalities Immunization Medical treatment Meningitis Sensitivity analysis Vaccines |
| title | Economic evaluation ofHaemophilus influenzaetype b vaccination in Moscow, Russian Federation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A20%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20evaluation%20ofHaemophilus%20influenzaetype%20b%20vaccination%20in%20Moscow,%20Russian%20Federation&rft.jtitle=Vaccine&rft.au=Platonov,%20AE&rft.date=2006-03-20&rft.volume=24&rft.issue=13&rft.spage=2367&rft.pages=2367-&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2005.11.054&rft_dat=%3Cproquest%3E3379200111%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547142787&rft_id=info:pmid/&rfr_iscdi=true |